PeptidPRO Slavinorm (vascular polypeptides) lyophilisate 5mg x 10pcs

bovine vascular polypeptides - 5.0 mg.
glycine - 20.0 mg.
Slavinorm® is used to increase pain-free walking distance in adult patients with chronic occlusive diseases of the arteries of the lower extremities of stage I-II according to the Fontaine classification
Slavinorm® is a complex of polypeptides isolated from the blood vessels of cattle.
The drug Slavinorm® is a peptide regulator that triggers a cascade of metabolic reactions leading to a decrease in lipid peroxidation, as a result of which it normalizes the function of the endothelium of the vascular wall; prevents the development of atherosclerosis by improving the atherogenicity coefficient (increasing the content of high-density lipoproteins and reducing atherogenic fractions of cholesterol), as well as reducing the level of triglycerides in the blood. Prevents the development of hypercoagulation due to its influence on the processes of blood coagulation and fibrinolysis, as a result of which it restores microcirculation in organs and tissues in various diseases and pathological conditions caused by atherosclerotic vascular damage.
According to the results of randomized, double-blind, placebo-controlled clinical trials, a course of use of the drug Slavinorm® as part of complex therapy significantly increases the ankle-brachial index (ABI), which is an objective indicator of improved blood circulation (reduction of the degree of ischemia) in the lower extremities in obliterating diseases, and also leads to a significant reduction in the symptoms of intermittent claudication: an increase in the distance of pain-free walking and the maximum distance walked compared to placebo in patients with chronic obliterating diseases of the arteries of the lower extremities.
The effect of Slavinorm® lasts for at least 7-10 days after the last administration of the drug; the continuation of the therapeutic effect at a later date after a course of treatment has not been studied in clinical studies.
The effect of the drug Slavinorm® on long-term outcomes of the disease (frequency of amputations, cardiovascular complications and mortality of patients with chronic occlusive diseases of the arteries of the lower extremities) has not been studied in clinical studies.

The drug is administered intramuscularly.
Before injection, the contents of the bottle are dissolved in 1-2 ml of 0.9% sodium chloride solution, directing the needle to the wall of the bottle to avoid foaming.
The drug is administered intramuscularly in 1 bottle (5 mg) once a day, 2 times a week, the course of treatment is 10 injections. If an injection is missed, it is not recommended to administer a double dose; the next dose of the drug is administered at the usual time of the next scheduled day.
The drug Slavinorm® is administered intramuscularly into the upper outer quadrant of the gluteus maximus muscle; it is necessary to alternate administration of the drug into the left and right gluteal muscles.

Storing a bottle with a dissolved drug and delayed administration of the reconstituted solution is unacceptable.
No special precautions are required when disposing of unused drugs.
With parenteral administration of drugs containing animal protein, allergic/anaphylactic reactions may develop. If allergic reactions occur when using the drug Slavinorm®, administration of the drug should be stopped and standard measures aimed at treating the allergic reaction should be carried out. During clinical studies, no allergic reactions to the drug were detected.
The use of the drug Slavinorm® for chronic obliterating diseases of the arteries of the lower extremities (COZANK) stages III-IV according to the Fontaine classification has not been studied in clinical studies.
There is no experience with repeated courses of use of the drug Slavinorm®.